Global Next-generation Cancer Diagnostic Market Overview:
Global Next-generation Cancer Diagnostic Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2024-2035, Considering the Base Year As 2025.
Global Next-generation Cancer Diagnostic Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2024-2035, with base year as 2025. This research study of Next-generation Cancer Diagnostic involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Next-generation Cancer Diagnostic Market:
The Next-generation Cancer Diagnostic Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Next-generation Cancer Diagnostic Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Next-generation Cancer Diagnostic Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Next-generation Cancer Diagnostic market has been segmented into:
Genetic Testing
Liquid Biopsy
Immunoassays
Next Generation Sequencing
Radiomics
By Application, Next-generation Cancer Diagnostic market has been segmented into:
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Leukemia
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Next-generation Cancer Diagnostic market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Next-generation Cancer Diagnostic market.
Top Key Players Covered in Next-generation Cancer Diagnostic market are:
Exact Sciences
Siemens Healthineers
Guardant Health
HoffmannLa Roche
Abbott Laboratories
Illumina
Qiagen
BioRad Laboratories
Genomic Health
Thermo Fisher Scientific
Agilent Technologies
Hologic
PerkinElmer
NanoString Technologies
Roche
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Next-generation Cancer Diagnostic Market Type
4.1 Next-generation Cancer Diagnostic Market Snapshot and Growth Engine
4.2 Next-generation Cancer Diagnostic Market Overview
4.3 Genetic Testing
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
4.3.3 Genetic Testing: Geographic Segmentation Analysis
4.4 Liquid Biopsy
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
4.4.3 Liquid Biopsy: Geographic Segmentation Analysis
4.5 Immunoassays
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
4.5.3 Immunoassays: Geographic Segmentation Analysis
4.6 Next Generation Sequencing
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
4.6.3 Next Generation Sequencing: Geographic Segmentation Analysis
4.7 Radiomics
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
4.7.3 Radiomics: Geographic Segmentation Analysis
Chapter 5: Next-generation Cancer Diagnostic Market Application
5.1 Next-generation Cancer Diagnostic Market Snapshot and Growth Engine
5.2 Next-generation Cancer Diagnostic Market Overview
5.3 Breast Cancer
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
5.3.3 Breast Cancer: Geographic Segmentation Analysis
5.4 Lung Cancer
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
5.4.3 Lung Cancer: Geographic Segmentation Analysis
5.5 Colorectal Cancer
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
5.5.3 Colorectal Cancer: Geographic Segmentation Analysis
5.6 Prostate Cancer
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
5.6.3 Prostate Cancer: Geographic Segmentation Analysis
5.7 Leukemia
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
5.7.3 Leukemia: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Next-generation Cancer Diagnostic Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 EXACT SCIENCES
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 SIEMENS HEALTHINEERS
6.4 GUARDANT HEALTH
6.5 HOFFMANNLA ROCHE
6.6 ABBOTT LABORATORIES
6.7 ILLUMINA
6.8 QIAGEN
6.9 BIORAD LABORATORIES
6.10 GENOMIC HEALTH
6.11 THERMO FISHER SCIENTIFIC
6.12 AGILENT TECHNOLOGIES
6.13 HOLOGIC
6.14 PERKINELMER
6.15 NANOSTRING TECHNOLOGIES
6.16 ROCHE
Chapter 7: Global Next-generation Cancer Diagnostic Market By Region
7.1 Overview
7.2. North America Next-generation Cancer Diagnostic Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Genetic Testing
7.2.2.2 Liquid Biopsy
7.2.2.3 Immunoassays
7.2.2.4 Next Generation Sequencing
7.2.2.5 Radiomics
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Breast Cancer
7.2.3.2 Lung Cancer
7.2.3.3 Colorectal Cancer
7.2.3.4 Prostate Cancer
7.2.3.5 Leukemia
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Next-generation Cancer Diagnostic Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Genetic Testing
7.3.2.2 Liquid Biopsy
7.3.2.3 Immunoassays
7.3.2.4 Next Generation Sequencing
7.3.2.5 Radiomics
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Breast Cancer
7.3.3.2 Lung Cancer
7.3.3.3 Colorectal Cancer
7.3.3.4 Prostate Cancer
7.3.3.5 Leukemia
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Next-generation Cancer Diagnostic Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Genetic Testing
7.4.2.2 Liquid Biopsy
7.4.2.3 Immunoassays
7.4.2.4 Next Generation Sequencing
7.4.2.5 Radiomics
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Breast Cancer
7.4.3.2 Lung Cancer
7.4.3.3 Colorectal Cancer
7.4.3.4 Prostate Cancer
7.4.3.5 Leukemia
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Next-generation Cancer Diagnostic Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Genetic Testing
7.5.2.2 Liquid Biopsy
7.5.2.3 Immunoassays
7.5.2.4 Next Generation Sequencing
7.5.2.5 Radiomics
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Breast Cancer
7.5.3.2 Lung Cancer
7.5.3.3 Colorectal Cancer
7.5.3.4 Prostate Cancer
7.5.3.5 Leukemia
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Next-generation Cancer Diagnostic Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Genetic Testing
7.6.2.2 Liquid Biopsy
7.6.2.3 Immunoassays
7.6.2.4 Next Generation Sequencing
7.6.2.5 Radiomics
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Breast Cancer
7.6.3.2 Lung Cancer
7.6.3.3 Colorectal Cancer
7.6.3.4 Prostate Cancer
7.6.3.5 Leukemia
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Next-generation Cancer Diagnostic Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Genetic Testing
7.7.2.2 Liquid Biopsy
7.7.2.3 Immunoassays
7.7.2.4 Next Generation Sequencing
7.7.2.5 Radiomics
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Breast Cancer
7.7.3.2 Lung Cancer
7.7.3.3 Colorectal Cancer
7.7.3.4 Prostate Cancer
7.7.3.5 Leukemia
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Next-generation Cancer Diagnostic Scope:
|
Report Data
|
Next-generation Cancer Diagnostic Market
|
|
Next-generation Cancer Diagnostic Market Size in 2025
|
USD XX million
|
|
Next-generation Cancer Diagnostic CAGR 2025 - 2032
|
XX%
|
|
Next-generation Cancer Diagnostic Base Year
|
2024
|
|
Next-generation Cancer Diagnostic Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Exact Sciences, Siemens Healthineers, Guardant Health, HoffmannLa Roche, Abbott Laboratories, Illumina, Qiagen, BioRad Laboratories, Genomic Health, Thermo Fisher Scientific, Agilent Technologies, Hologic, PerkinElmer, NanoString Technologies, Roche.
|
|
Key Segments
|
By Type
Genetic Testing
Liquid Biopsy
Immunoassays
Next Generation Sequencing
Radiomics
By Applications
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Leukemia
|
